Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 3, 2016, Pages 528-535

  Wang, Li ^a   Fonnesbeck, Christopher ^a   Simons, Rhea ^a   Summers, Chelsey ^a   Bourgeois, John ^a   Clifton, Carey ^a   Vaughan, Leigh Ann ^a   Lucid, Catherine ^a   Jagasia, Madan ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic stem cell transplantation; Influenza; Vaccination

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; PREDNISONE; VIRUS ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; INJECTION SITE COLORATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS STRAIN; ALLOGRAFT; ANTIBODY SPECIFICITY; BLOOD; CLINICAL TRIAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; YOUNG ADULT;

ADULT; ALLOGRAFTS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MALE; YOUNG ADULT;

EID: 85009452980     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.12.003     Document Type: Article

References (56)

1. 1 HCT Trends and Survival Data. Available at: http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx.
2. 2 Boeckh, M., The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 143 (2008), 455–467.
3. 3 Gooley, T.A., Chien, J.W., Pergam, S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363 (2010), 2091–2101.
4. 4 Hashmi, S., Carpenter, P., Khera, N., et al. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant 21 (2015), 225–232.
5. 5 Slides and reports. Available at: http://www.cibmtr.org/ReferenceCenter/SlidesReports/Pages/index.aspx.
6. 6 Denzen, E.M., Majhail, N.S., Stickney Ferguson, S., et al. Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative. Biol Blood Marrow Transplant 19 (2013), 4–11.
7. 7 Majhail, N.S., Tao, L., Bredeson, C., et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant 19 (2013), 1498–1501.
8. 8 Machado, C.M., Cardoso, M.R., da Rocha, I.F., et al. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 36 (2005), 897–900.
9. 9 Whimbey, E., Elting, L.S., Couch, R.B., et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 13 (1994), 437–440.
10. 10 Ljungman, P., Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 7:Suppl (2001), 5S–7S.
11. 11 Whimbey, E., Champlin, R.E., Couch, R.B., et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 22 (1996), 778–782.
12. 12 Bowden, R.A., Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 102:3A (1997), 27–30 discussion 42–23.
13. 13 Engelhard, D., Mohty, B., de la Camara, R., et al. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15 (2013), 219–232.
14. 14 Hicks, K.L., Chemaly, R.F., Kontoyiannis, D.P., Common community respiratory viruses in patients with cancer: more than just “common colds”. Cancer 97 (2003), 2576–2587.
15. 15 Kempe, A., Hall, C.B., MacDonald, N.E., et al. Influenza in children with cancer. J Pediatr 115 (1989), 33–39.
16. 16 Nichols, W.G., Guthrie, K.A., Corey, L., Boeckh, M., Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39 (2004), 1300–1306.
17. 17 Morrison, C., Maurtua-Neumann, P., Myint, M.T., et al. Pandemic (H1N1) 2009 outbreak at camp for children with hematologic and oncologic conditions. Emerg Infect Dis 17 (2011), 87–89.
18. 18 Kharfan-Dabaja, M.A., Velez, A., Richards, K., et al. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol 91 (2010), 124–127.
19. 19 Suyani, E., Aki, Z., Guzel, O., et al. H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving. Transpl Infect Dis 13 (2011), 208–212.
20. 20 George, B., Ferguson, P., Kerridge, I., et al. The clinical impact of infection with swine flu (H1N109) strain of influenza virus in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 17 (2011), 147–153.
21. 21 Taplitz, R., Espinosa-Aguilar, L., Green, J., et al. Novel H1N1 influenza in hematopoietic stem cell transplant recipients: two center's experience. Biol Blood Marrow Transplant 17 (2011), 566–573.
22. 22 Campbell, A.P., Jacob, S.T., Kuypers, J., et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med 152 (2010), 619–620.
23. 23 Mohty, B., Thomas, Y., Vukicevic, M., et al. Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. Bone Marrow Transplant 47 (2012), 236–242.
24. 24 Nozoe, M., Iino, T., Nagafuji, K., et al. Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma. Intern Med 42 (2003), 1127–1130.
25. 25 Engelhard, D., Nagler, A., Hardan, I., et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11 (1993), 1–5.
26. 26 Gandhi, M.K., Egner, W., Sizer, L., et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant 28 (2001), 775–781.
27. 27 Haining, W.N., Evans, J.W., Seth, N.P., et al. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol 127 (2004), 322–325.
28. 28 Avetisyan, G., Ragnavolgyi, E., Toth, G.T., et al. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Bone Marrow Transplant 36 (2005), 411–415.
29. 29 Avetisyan, G., Aschan, J., Hassan, M., Ljungman, P., Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 86 (2008), 257–263.
30. 30 Gelinck, L.B., van den Bemt, B.J., Marijt, W.A., et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 27 (2009), 2469–2474.
31. 31 Yalcin, S.S., Kondolot, M., Albayrak, N., et al. Serological response to influenza vaccine after hematopoietic stem cell transplantation. Ann Hematol 89 (2010), 913–918.
32. 32 Seidel, A., Smith, D., Yung, E., et al. CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults. Biol Blood Marrow Transplant 17 (2011), 524–533.
33. 33 Engelhard, D., Zakay-Rones, Z., Shapira, M.Y., et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 29 (2011), 1777–1782.
34. 34 Issa, N.C., Marty, F.M., Gagne, L.S., et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 17 (2011), 434–438.
35. 35 Karras, N.A., Weeres, M., Sessions, W., et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant 19 (2013), 109–116.
36. 36 Pauksen, K., Linde, A., Hammarstrom, V., et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 30 (2000), 342–348.
37. 37 Mohty, B., Bel, M., Vukicevic, M., et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 96 (2011), 896–904.
38. 38 Gueller, S., Allwinn, R., Mousset, S., et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17 (2011), 1546–1550.
39. 39 Roll, D., Ammer, J., Holler, B., et al. Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Infection 40 (2012), 153–161.
40. 40 Falsey, A.R., Treanor, J.J., Tornieporth, N., et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200 (2009), 172–180.
41. 41 Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 59 (2010), 485–486.
42. 42 Couch, R.B., Winokur, P., Brady, R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25 (2007), 7656–7663.
43. 43 Keitel, W.A., Atmar, R.L., Cate, T.R., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166 (2006), 1121–1127.
44. 44 Kendal, A.P., Pereira, M.S., Skehel, J.J., (eds.) Concepts and procedures for laboratory-based influenza surveillance, 1982, Centers for Disease Control and Prevention, Atlanta.
45. 45 Keitel, W.A., Cate, T.R., Atmar, R.L., et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 3 (1996), 507–510.
46. 46 GiaQuinta, S., Michaels, M.G., McCullers, J.A., et al. Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant 19 (2015), 219–228.
47. 47 McManus, M., Frangoul, H., McCullers, J.A., et al. Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer 61 (2014), 815–820.
48. 48 DiazGranados, C.A., Dunning, A.J., Kimmel, M., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 371 (2014), 635–645.
49. 49 WHO Expert Committee on biological standardization. World Health Organ Tech Rep Ser 963 (2011), 1–244.
50. 50 Krause, J.C., Tsibane, T., Tumpey, T.M., et al. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85 (2011), 10905–10908.
51. 51 Epstein, S.L., Garcia, M., Survey of human antibody responses to influenza virus matrix protein 2 by use of a sensitive flow cytometric method. J Infect Dis 209 (2014), 975–977.
52. 52 Pena, L., Vincent, A.L., Ye, J., et al. Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J Virol 85 (2011), 456–469.
53. 53 Berthoud, T.K., Hamill, M., Lillie, P.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52 (2011), 1–7.
54. 54 Zhang, W., Wang, L., Liu, Y., et al. Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis. Pharm Res 31 (2014), 1015–1031.
55. 55 Behzad, H., Huckriede, A.L., Haynes, L., et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 205 (2012), 466–473.
56. 56 Rubin, L.G., Levin, M.J., Ljungman, P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58 (2014), e44–100.